HYBRID EVENT: Join us in person in London, UK or attend virtually from anywhere.
Myocarditis in neonates, a condition characterized by inflammation of the heart muscle in infants under 28 days of age, represents a rare but potentially life-threatening challenge in Paediatric cardiology. The etiology of neonatal myocarditis is diverse, ranging from viral and bacterial infections to autoimmune reactions, often making accurate diagnosis a complex endeavor. This inflammatory process can disrupt the delicate balance of the neonatal cardiovascular system, leading to a spectrum of clinical manifestations, from subtle symptoms such as irritability and poor feeding to more severe presentations like respiratory distress, cardiogenic shock, or sudden cardiac death. The clinical course is often rapid and unpredictable, necessitating a high index of suspicion among healthcare providers. Diagnostic modalities, including echocardiography, cardiac biomarkers, and, in some cases, endomyocardial biopsy, play a pivotal role in confirming the diagnosis. Management strategies involve a multidisciplinary approach, encompassing supportive care, antiviral or antimicrobial therapy, and, in severe cases, mechanical circulatory support. The challenges in treating neonatal myocarditis are exacerbated by the vulnerability of this patient population, necessitating nuanced considerations in medication dosing and monitoring. Despite advancements in medical care, the prognosis remains guarded, and long-term outcomes may be influenced by factors such as the underlying cause, timely intervention, and the extent of myocardial damage. Ongoing research seeks to refine our understanding of the pathophysiology and optimal management strategies for this complex and multifaceted condition, aiming to improve outcomes and guide clinicians in navigating the intricate landscape of neonatal myocarditis.
